Cancer Forums and News by PhD's

News | Forums

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News


Cancer Review


Recent Forum Topics

Chemotherapy plus radiation prevents bladder cancer recurrences
By Dross at 2010-10-26 01:59

Adding chemotherapyterm to radiation therapy for muscle invasive bladder cancer allows 67 percent of people to be free of disease in their bladders two years after treatment. This compares to 54 percent of people who receive radiation alone, according to the largest randomized study of its kind presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

read more | 1365 reads

Patients unaware of link between smoking and bladder cancer
By Dross at 2008-07-08 20:55

ANN ARBOR, Mich. - Even though cigarette smoking accounts for up to half of all bladder cancer cases, few people are aware of the connection - including more than three-quarters of patients who have bladder cancer, according to a new study from the University of Michigan Comprehensive Cancer Center.

This knowledge vacuum suggests that urologists and other physicians need to do a much better job of telling patients about the risk of smoking and encourage them to quit, the study authors say.

"The general public understands that cigarette smoking can lead to lung cancer, but very few people understand that it also can lead to bladder cancer," says senior author James E. Montie, M.D., Valassis Professor of Urologic Oncology at the U-M Health System.

read more | 1159 reads

AUA releases new guidelines on non-muscle invasive bladder cancer
By Dross at 2007-11-10 22:54

LINTHICUM, MD. The AUA is pleased to announce their new Guideline on the Management of Nonmuscle Invasive Bladder Cancer. Each year, more than 60,000 people are diagnosed with bladder cancer, which has been linked to a number of risk factors, including cigarette smoking and exposure to hazardous chemicals. The AUA originally published its guideline in 1999 and the report issued today is an update to that document.

The Guideline focuses on current treatment impacts on outcomes of interest to the patient, such as efficacy outcomes and occurrence of complications and side effectsterm in treated patients. Unfortunately, new evidence on treatment modalities is scant and advances in treatment and physician education regarding treatment are limited.

read more | 2 comments | 1115 reads

Scientists find one reason why bladder cancer hits more men
By Dross at 2007-04-22 00:45

Scientists have discovered one of the reasons why bladder cancer is so much more prevalent in men than women: A molecular receptor or protein that is much more active in men than women plays a role in the development of the disease. The finding could open the door to new types of treatment with the disease.

In an article in the April 4 issue of the Journal of the National Cancer Institute, Chawnshang Chang, Ph.D., of the University of Rochester Medical Center and colleagues show that the androgen receptor, which is central to the action of testosterone and other hormones that are much more plentiful in men than women, appears to play a key role in the disease.

read more | 1393 reads

Bladder Cancer Basics
By Dross at 2007-02-19 06:40

Definition of bladder cancer: Cancer that forms in tissues of the bladder (the organ that stores urine). Most bladder cancers are transitional cell carcinomas (cancer that begins in cells that normally make up the inner lining of the bladder). Other types include squamous cell carcinomaterm (cancer that begins in thin, flat cells) and adenocarcinomaterm (cancer that begins in cells that make and release mucus and other fluids). The cells that form squamous cell carcinoma and adenocarcinoma develop in the inner lining of the bladder as a result of chronic irritation and inflammation.

read more | 1 comment | 18899 reads

New biomarker test could predict outcome for bladder cancer patients
By Dross at 2007-02-01 23:58

A set of molecular biomarkers might better predict the recurrence of bladder cancer than conventional prognostic features such as the stage or grade of the malignancy at the time it is discovered, UT Southwestern Medical Center researchers have found. Once a patient undergoes surgery for the removal of their bladder and lymph nodes -- the standard treatment for muscle-invasive bladder cancer -- researchers say a routine tissue analysis could easily test for the presence of mutated proteins, or biomarkers, that they found to help ascertain the chances that the cancer will return.


read more | 1387 reads

Advanced Transitional Cell Carcinoma treatment with Docetaxel and Gemcitabine Phase II study
By HCat at 2007-01-10 06:06

    Transitional cell carcinomaterm (TCC) of the urothelium (these are epithelial cells that mainly line the urinary tract) is usually treated with a combination regimen of methotrexate/vinblastine/doxorubicine/cisplatin (known as M-VAC). Recent reports from a phase III trial showed that M-VAC versus gemcitabine plus cisplatin (GC) had similar response rates, time to progression and overall survival. However, GC was less toxic than M-VAC and the need for overall survival improvement needed to be increased. This article presents a phase II study of a combination of gemcitabine and docetaxel. Gemcitabine [Gemzar from Eli Lilly] is a DNA analogue that inhibits DNA synthesis ultimately leading to cell death. Docetaxel [Taxotere from Sanofi Aventis] is a paclitaxel analogue that stabilizes tubulin ultimately preventing cellular division and leading to cell death. These two drugs are thought to have a synergistic effect. That is, the combination effect of the two drugs is greater than that predicted from the effects from single drug therapy.

    The trial included 34 patients with advanced TCC that was unresectable for cure or had measurable metastasistermterm were non-randomly selected with primary tumor sites being 26 bladder, 5 kidney, and 3 ureter. 7 patients had previous chemotherapyterm (21%). 82% had previous surgery to remove the primary tumor, with 20 patients having some form of metastasis. Haematologic (blood) toxicity was common during treatment (24% in some side effectsterm). A complete response (CR) was seen in 2 patients (5.8%) where all lesions or growths disappeared. A partial response (PR) was seen in 16 patients where the lesion or growth size was decreased by 30% or more. This gave an overall response rate (OR) of 53%. One aspect the study noted was a shift in the distribution of gemcitabine from the plasmid to the red blood cells (RBC).
One part the researchers note in the study is the high OR rate. Other studies of this combination of drug have shown OR rates of 17% as a second line and 33% as a first line of treatment. The researchers suggests the reason for the better response rate in their study is their study has a larger number of patients who have never been treated with chemo drugs (chemotherapy-naïve) and has a more favorable drug administration schedule.

read more | 4016 reads

Syndicate content

sponsored links



Subscribe to our newsletter to receive info on our site or upcoming clinical trials

Confirm your email address

HTML format

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate

Syndicate content

All times are GMT -5. The time now is 07:26 PM.